Literature DB >> 25740107

The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.

Hidemasa Matsuo1, Susumu Goyama2, Yasuhiko Kamikubo1, Souichi Adachi3.   

Abstract

Entities:  

Keywords:  EVI1; PRDM16; acute myeloid leukemia

Mesh：

Substances：

Year:  2015        PMID： 25740107      PMCID： PMC4349293          DOI： 10.3324/haematol.2015.124396

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Evi-1 as a critical regulator of leukemic cells.

Authors:  Susumu Goyama; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-06-08       Impact factor: 2.490

2.  High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.

Authors:  A Jo; S Mitani; N Shiba; Y Hayashi; Y Hara; H Takahashi; I Tsukimoto; A Tawa; K Horibe; D Tomizawa; T Taga; S Adachi; T Yoshida; H Ichikawa
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

3.  The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features.

Authors:  Marion Eveillard; Jacques Delaunay; Steven Richebourg; Laurence Lodé; Richard Garand; Soraya Wuillème; François Duhoux; Hélène Antoine-Poirel; Catherine Godon; Marie C Béné
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

4.  EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Mio Kajihara; Daisuke Tomizawa; Tomoyuki Watanabe; Akiko Moriya Saito; Junichiro Fujimoto; Keizo Horibe; Kumi Kodama; Mayu Tokumasu; Hiroshi Itoh; Hideki Nakayama; Akitoshi Kinoshita; Takashi Taga; Akio Tawa; Tomohiko Taki; Norio Shiba; Kentaro Ohki; Yasuhide Hayashi; Yuka Yamashita; Akira Shimada; Shiro Tanaka; Souichi Adachi
Journal:  Haematologica       Date:  2014-07-11       Impact factor: 9.941

5.  Prdm16 is a physiologic regulator of hematopoietic stem cells.

Authors:  Francesca Aguilo; Serine Avagyan; Amy Labar; Ana Sevilla; Dung-Fang Lee; Parameet Kumar; Ihor R Lemischka; Betty Y Zhou; Hans-Willem Snoeck
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

6.  PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.

Authors:  Francois P Duhoux; Geneviève Ameye; Carmen P Montano-Almendras; Khadija Bahloula; Marie J Mozziconacci; Sophy Laibe; Iwona Wlodarska; Lucienne Michaux; Pascaline Talmant; Steven Richebourg; Eric Lippert; Frank Speleman; Christian Herens; Stéphanie Struski; Sophie Raynaud; Nathalie Auger; Nathalie Nadal; Katrina Rack; Francine Mugneret; Isabelle Tigaud; Marina Lafage; Sylvie Taviaux; Catherine Roche-Lestienne; Dominique Latinne; Jeanne M Libouton; Jean-Baptiste Demoulin; Hélène A Poirel
Journal:  Br J Haematol       Date:  2011-11-03       Impact factor: 6.998

7.  An MLL-dependent network sustains hematopoiesis.

Authors:  Erika L Artinger; Bibhu P Mishra; Kristin M Zaffuto; Bin E Li; Elaine K Y Chung; Adrian W Moore; Yufei Chen; Chao Cheng; Patricia Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-06       Impact factor: 11.205

Review 8.  Leukemogenesis of the EVI1/MEL1 gene family.

Authors:  Kazuhiro Morishita
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

9.  Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells.

Authors:  Susumu Goyama; Go Yamamoto; Munetake Shimabe; Tomohiko Sato; Motoshi Ichikawa; Seishi Ogawa; Shigeru Chiba; Mineo Kurokawa
Journal:  Cell Stem Cell       Date:  2008-08-07       Impact factor: 24.633

10.  HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis.

Authors:  Frederik Otzen Bagger; Nicolas Rapin; Kim Theilgaard-Mönch; Bogumil Kaczkowski; Lina A Thoren; Johan Jendholm; Ole Winther; Bo T Porse
Journal:  Nucleic Acids Res       Date:  2012-11-09       Impact factor: 16.971
  10 in total
  9 in total

1.  PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.

Authors:  David J Corrigan; Larry L Luchsinger; Mariana Justino de Almeida; Linda J Williams; Alexandros Strikoudis; Hans-Willem Snoeck
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

2.  Mapping Whole-Transcriptome Splicing in Mouse Hematopoietic Stem Cells.

Authors:  Oron Goldstein; Karin Meyer; Yariv Greenshpan; Nir Bujanover; Mili Feigin; Hadas Ner-Gaon; Tal Shay; Roi Gazit
Journal:  Stem Cell Reports       Date:  2016-12-29       Impact factor: 7.765

Review 3.  Epigenetics in normal and malignant hematopoiesis: An overview and update 2017.

Authors:  Susumu Goyama; Toshio Kitamura
Journal:  Cancer Sci       Date:  2017-04-20       Impact factor: 6.716

4.  Loss of Asxl2 leads to myeloid malignancies in mice.

Authors:  Jianping Li; Fuhong He; Peng Zhang; Shi Chen; Hui Shi; Yanling Sun; Ying Guo; Hui Yang; Na Man; Sarah Greenblatt; Zhaomin Li; Zhengyu Guo; Yuan Zhou; Lan Wang; Lluis Morey; Sion Williams; Xi Chen; Qun-Tian Wang; Stephen D Nimer; Peng Yu; Qian-Fei Wang; Mingjiang Xu; Feng-Chun Yang
Journal:  Nat Commun       Date:  2017-06-08       Impact factor: 14.919

5.  High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy.

Authors:  Ya-Zhen Qin; Ting Zhao; Hong-Hu Zhu; Jing Wang; Jin-Song Jia; Yue-Yun Lai; Xiao-Su Zhao; Hong-Xia Shi; Yan-Rong Liu; Hao Jiang; Xiao-Jun Huang; Qian Jiang
Journal:  Med Sci Monit       Date:  2018-02-06

6.  Detection of genetic alterations in gastric cancer patients from Saudi Arabia using comparative genomic hybridization (CGH).

Authors:  Fehmida Bibi; Isse Ali; Muhammad Imran Naseer; Hussein Sheikh Ali Mohamoud; Muhammad Yasir; Sana Akhtar Alvi; Asif Ahmed Jiman-Fatani; Ali Sawan; Esam Ibraheem Azhar
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

7.  MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia.

Authors:  Mingshan Niu; Ninghan Zhang; Rong Wang; Tingting Shao; Yuan Feng; Yangling Shen; Xuejiao Liu; Kai Zhao; Shengyun Zhu; Linyan Xu; Yao Yao; Kailin Xu
Journal:  Front Oncol       Date:  2019-10-11       Impact factor: 6.244

8.  Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.

Authors:  Hui Yang; Stefan Kurtenbach; Ying Guo; Ines Lohse; Michael A Durante; Jianping Li; Zhaomin Li; Hassan Al-Ali; Lingxiao Li; Zizhen Chen; Matthew G Field; Peng Zhang; Shi Chen; Shohei Yamamoto; Zhuo Li; Yuan Zhou; Stephen D Nimer; J William Harbour; Claes Wahlestedt; Mingjiang Xu; Feng-Chun Yang
Journal:  Blood       Date:  2017-11-07       Impact factor: 25.476

Review 9.  Multifaceted Role of PRDM Proteins in Human Cancer.

Authors:  Amelia Casamassimi; Monica Rienzo; Erika Di Zazzo; Anna Sorrentino; Donatella Fiore; Maria Chiara Proto; Bruno Moncharmont; Patrizia Gazzerro; Maurizio Bifulco; Ciro Abbondanza
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.